Experic
Contract Manufacturing Organisation and Pharmaceutical Supply Services
The likelihood of approval (LoA) for AMO Pharma’s AMO-01 in Phelan-McDermid Syndrome (PMS) with co-morbid epilepsy jumped 13 points as of 29 March, according to GlobalData’s LoA data.
The likelihood of approval (LoA) for AMO Pharma’s AMO-01 in Phelan-McDermid Syndrome (PMS) with co-morbid epilepsy jumped 13 points as of 29 March, according to GlobalData’s LoA data. The score change was based on the completion of an investigator-sponsored, 6-patient Phase II at Mount Sinai Hospital on 31 March 2020, noted by a 24 March 2021 update to ClinicalTrials.gov.
London, UK-based AMO Pharma’s open-label Phase II (NCT03493607), which has not yet published results, used the number of adverse events during the eight weeks following administration as its primary endpoint. Secondary endpoints include physician-measured efficacy assessments such as the Clinical Global Impression – Improvement Scale and the Visual Analogue Scale. Subjects received a single, 6-hour intravenous infusion of AMO-01 at the onset of the study, totalling 120 mg/m2 of treatment, according to Clinical Trials.gov. AMO Pharma provided AMO-01 and grant funding for the investigator-sponsored trial, according to a May 2018 company press release.
While the LoA prior to this news was 5%, GlobalData’s analysis using a combination of machine learning and a proprietary algorithm has raised the LoA to 18%. AMO-01 inhibits the Ras-extracellular signal-regulated kinase pathway inhibitor, which could improve behavioural abnormalities and seizures in patients with the neurodevelopment disorder PMS.
William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.
Contract Manufacturing Organisation and Pharmaceutical Supply Services
ZUMEDU Secure Peer-to-Peer Video Conference Solutions for Clinical Researchers
Functional Service Provider